BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1036 related articles for article (PubMed ID: 28541315)

  • 1. Therapeutic T cell engineering.
    Sadelain M; Rivière I; Riddell S
    Nature; 2017 May; 545(7655):423-431. PubMed ID: 28541315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR T cells: Building on the CD19 paradigm.
    Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
    Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy.
    Mock U; Nickolay L; Philip B; Cheung GW; Zhan H; Johnston ICD; Kaiser AD; Peggs K; Pule M; Thrasher AJ; Qasim W
    Cytotherapy; 2016 Aug; 18(8):1002-1011. PubMed ID: 27378344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology.
    Ebert LM; Yu W; Gargett T; Brown MP
    Biochem Soc Trans; 2018 Apr; 46(2):391-401. PubMed ID: 29540509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retargeting CD19 Chimeric Antigen Receptor T Cells via Engineered CD19-Fusion Proteins.
    Klesmith JR; Su L; Wu L; Schrack IA; Dufort FJ; Birt A; Ambrose C; Hackel BJ; Lobb RR; Rennert PD
    Mol Pharm; 2019 Aug; 16(8):3544-3558. PubMed ID: 31242389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials.
    Arabi F; Torabi-Rahvar M; Shariati A; Ahmadbeigi N; Naderi M
    Exp Cell Res; 2018 Aug; 369(1):1-10. PubMed ID: 29758187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Principles of Engineering Immune Cells to Treat Cancer.
    Lim WA; June CH
    Cell; 2017 Feb; 168(4):724-740. PubMed ID: 28187291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging Cellular Therapies for Cancer.
    Guedan S; Ruella M; June CH
    Annu Rev Immunol; 2019 Apr; 37():145-171. PubMed ID: 30526160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FLAG-tagged CD19-specific CAR-T cells eliminate CD19-bearing solid tumor cells
    Berahovich R; Xu S; Zhou H; Harto H; Xu Q; Garcia A; Liu F; Golubovskaya VM; Wu L
    Front Biosci (Landmark Ed); 2017 Jun; 22(10):1644-1654. PubMed ID: 28410137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 11. What CAR Will Win the CD19 Race?
    Quintás-Cardama A
    Mol Cancer Ther; 2019 Mar; 18(3):498-506. PubMed ID: 30824581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered T cells: the promise and challenges of cancer immunotherapy.
    Fesnak AD; June CH; Levine BL
    Nat Rev Cancer; 2016 Aug; 16(9):566-81. PubMed ID: 27550819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CART trials are going ahead.
    Wei J; Han W
    Sci China Life Sci; 2017 Nov; 60(11):1276-1279. PubMed ID: 29170890
    [No Abstract]   [Full Text] [Related]  

  • 15. IMMUNOLOGY. Fighting autoimmunity with immune cells.
    Leslie M
    Science; 2016 Jul; 353(6294):14. PubMed ID: 27365430
    [No Abstract]   [Full Text] [Related]  

  • 16. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell engineering as therapy for cancer and HIV: our synthetic future.
    June CH; Levine BL
    Philos Trans R Soc Lond B Biol Sci; 2015 Oct; 370(1680):20140374. PubMed ID: 26416683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The promise and potential pitfalls of chimeric antigen receptors.
    Sadelain M; Brentjens R; Rivière I
    Curr Opin Immunol; 2009 Apr; 21(2):215-23. PubMed ID: 19327974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road.
    Gill S; Porter DL
    Expert Opin Biol Ther; 2014 Jan; 14(1):37-49. PubMed ID: 24261468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.
    Rivière I; Sadelain M
    Mol Ther; 2017 May; 25(5):1117-1124. PubMed ID: 28456379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.